Mechanism of Wuling Capsules against hepatic fibrosis based on network pharmacology and animal experiments.
10.19540/j.cnki.cjcmm.20230707.501
- Author:
Nan LI
1
;
Su-Juan REN
1
;
Rui ZHOU
1
;
Zhong-Xing SONG
1
;
Yan-Ru LIU
1
;
Zhi-Shu TANG
2
;
Jian-Ping ZHOU
3
;
Zhao-Jun CAO
3
Author Information
1. Shaanxi University of Chinese Medicine/Shaanxi Collaborative Innovation Center of TCM Resource Industrialization/Shaanxi Innovative Drug Research Center Xianyang 712083, China.
2. Shaanxi University of Chinese Medicine/Shaanxi Collaborative Innovation Center of TCM Resource Industrialization/Shaanxi Innovative Drug Research Center Xianyang 712083, China Graduate School of China Academy of Chinese Medical Sciences Beijing 100700, China.
3. Tsinghua De Ren Xi'an Happiness Pharmaceutical Co., Ltd. Xi'an 710043, China.
- Publication Type:Journal Article
- Keywords:
PI3K-Akt signaling pathway;
Wuling Capsules;
animal experiment;
hepatic fibrosis;
molecular docking;
network pharmacology
- MeSH:
Animals;
Rats;
Interleukin-6;
Network Pharmacology;
Animal Experimentation;
Tumor Necrosis Factor-alpha;
Molecular Docking Simulation;
Phosphatidylinositol 3-Kinases;
Proto-Oncogene Proteins c-akt;
Liver Cirrhosis/genetics*;
Medicine, Chinese Traditional;
Capsules;
Class I Phosphatidylinositol 3-Kinases;
Collagen;
Drugs, Chinese Herbal/pharmacology*
- From:
China Journal of Chinese Materia Medica
2023;48(19):5365-5376
- CountryChina
- Language:Chinese
-
Abstract:
The present study aimed to explore the underlying mechanism of Wuling Capsules in the treatment of hepatic fibrosis(HF) through network pharmacology, molecular docking, and animal experiments. Firstly, the chemical components and targets of Wuling Capsules against HF were searched from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP), Traditional Chinese Medicines Integrated Database(TCMID), GeneCards, and literature retrieval. The protein-protein interaction(PPI) network analysis was carried out on the common targets by STRING database and Cytoscape 3.9.1 software, and the core targets were screened, followed by Gene Ontology(GO) and Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway enrichment analyses. Enrichment analysis was conducted on the core targets and the "drug-core component-target-pathway-disease" network was further constructed. Subsequently, molecular docking between core components and core targets was conducted using AutoDock Vina software to predict the underlying mechanism of action against HF. Finally, an HF model induced by CCl_4 was constructed in rats, and the general signs and liver tissue morphology were observed. HE and Masson staining were used to analyze the liver tissue sections. The effects of Wuling Capsules on the levels of inflammatory factors, hydroxyproline(HYP) levels, and core targets were analyzed by ELISA, RT-PCR, etc. A total of 445 chemical components of Wuling Capsules were screened, corresponding to 3 882 potential targets, intersecting with 1 240 targets of HF, and 47 core targets such as TNF, IL6, INS, and PIK3CA were screened. GO and KEGG enrichment analysis showed that the core targets mainly affected the process of cell stimulation response and metabolic regulation, involving cancer, PI3K-Akt, MAPK, and other signaling pathways. Molecular docking showed that the core components of Wuling Capsules, such as lucidenic acid K, ganoderic acid B, lucidenic acid N, saikosaponin Q2, and neocryptotanshinone, had high affinities with the core targets, such as TNF, IL6 and PIK3CA. Animal experiments showed that Wuling Capsules could reduce fat vacuole, inflammatory infiltration, and collagen deposition in rat liver, decrease the levels of inflammatory cytokines TNF-α, IL-6, and HYP, and downregulated the expressions of PI3K and Akt mRNA. This study suggests that the anti-HF effect of Wuling Capsules may be achieved by regulating the PI3K-Akt signaling pathway, reducing the levels of TNF-α and IL-6 inflammatory factors, and inhibiting the excessive deposition of collagen.
